Tiziana Life Sciences Doses First Patient in Alzheimer's Trial
Ticker: TLSA · Form: 6-K · Filed: Dec 17, 2025 · CIK: 1723069
Sentiment: neutral
Topics: clinical-trial, alzheimers, drug-development
TL;DR
Tiziana Life Sciences dosed first Alzheimer's patient with intranasal foralumab in Phase 2 trial.
AI Summary
On December 17, 2025, Tiziana Life Sciences LTD announced that the first patient has been dosed with intranasal foralumab in a Phase 2 clinical trial for early Alzheimer's disease. This marks a significant step in the company's research into potential treatments for AD.
Why It Matters
This event is a crucial step in evaluating foralumab's potential as a treatment for Alzheimer's disease, a condition with significant unmet medical needs.
Risk Assessment
Risk Level: medium — Clinical trial progress is inherently risky, with potential for delays, unexpected results, or regulatory hurdles.
Key Players & Entities
- Tiziana Life Sciences LTD (company) — Registrant
- foralumab (drug) — Investigational treatment
- Alzheimer's disease (disease) — Target condition
- December 17, 2025 (date) — Announcement date
FAQ
What is the specific designation of the clinical trial for intranasal foralumab in Alzheimer's patients?
The trial is a Phase 2 randomized, placebo-controlled clinical trial.
What is the name of the drug being tested?
The drug being tested is intranasal foralumab.
What stage of Alzheimer's disease is the trial targeting?
The trial is targeting patients with early Alzheimer's disease.
When was the announcement made regarding the first patient being dosed?
The announcement was made on December 17, 2025.
What is the principal executive office address of Tiziana Life Sciences LTD?
The principal executive office is located at 9th Floor, 107 Cheapside, London EC2V 6DN.
Filing Stats: 357 words · 1 min read · ~1 pages · Grade level 14.4 · Accepted 2025-12-17 08:45:26
Filing Documents
- ea0270048-6k_tiziana.htm (6-K) — 15KB
- ea027004801ex99-1_tiziana.htm (EX-99.1) — 14KB
- ex99-1_001.jpg (GRAPHIC) — 12KB
- 0001213900-25-122553.txt ( ) — 47KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. TIZIANA LIFE SCIENCES LTD Date: December 17, 2025 By: /s/ Keeren Shah Name: Keeren Shah Title: Chief Financial Officer 2 EXHIBIT INDEX Exhibit No. Description 99.1 Tiziana Life Sciences LTD Press Release, dated December 17, 2025 3